PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.
The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.